Japanese company Takeda Pharmaceutical Company is all set to collaborate with NuBiyota to develop microbial ecosystem therapeutic products for gastroenterology (GI) indications.
Under the partnership, NuBiyota’s microbiome platform for GI indications will be used to advance oral microbial consortia products.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In addition to receiving an upfront payment, NuBiyota is eligible for success-based development, regulatory and commercial milestones and tiered royalties based on net sales of the products.
Takeda Pharmaceutical Company gastroenterology therapeutic area unit head Asit Parikh said: “We are excited to partner with NuBiyota as this collaboration reinforces Takeda’s long-term commitment to unmet medical need in gastroenterology and adds to our other microbiome-related partnerships.
“Through these partnerships, we are exploring both microbial consortia and microbiome derived bioactives to investigate how the microbiome can be harnessed for treatment of GI diseases.”
NuBiyota clinic-ready, microbial consortia, microbial ecosystem therapeutic offers an entry point for clinical evaluation of microbiome based therapeutics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThese products will help improve understanding of the role of microbiota in GI disease.
Through specialised and strategic in-house development, external partnerships, in-licensing and acquisitions, Takeda has various early stage GI assets currently in development.
The company focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas with vaccines.
